|
|
Article: Seaside Therapeutics Recruits Industry Veterans to Accelerate Development of Candidates for Autism and Fragile X Syndrome.
- Article from:
- Business Wire
- Article date:
- October 14, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, MASS. -- Seaside Therapeutics LLC announced today the addition of three highly experienced industry executives to the Company's senior management team--Daniel E. Geffken as Chief Operating Officer, John C. Amedio, Jr., Ph.D., as Vice President, Manufacturing and Process Development and W. Roger Rush, Ph.D., as Vice President, Preclinical Development.
"Dan, John and Roger all bring a depth of valuable experience that directly and immediately supports the acceleration of Seaside's pipeline and research programs in disorders of brain development," said Randall L. Carpenter, M.D., President and Chief Executive Officer of Seaside Therapeutics. "They join an ...